Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285260149> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4285260149 endingPage "213" @default.
- W4285260149 startingPage "213" @default.
- W4285260149 abstract "COVID-19 vaccines, we believe, have come to rescue us from the clutches of the dreaded severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With rapid ongoing mutations, it is difficult to predict the effectiveness of seroconversion following vaccination. This study aims to find out the proportion of people with seroconversion following first dose of Covishield vaccine.Randomly selected health-care workers were followed up for SARS-CoV-2 immunoglobulin G (IgG) antibodies between 28 and 42 days after receiving their first vaccine dose. The VITROS SARS-CoV-2 IgG test (Ortho-Clinical Diagnostics, USA) with 100% specificity and > 90% sensitivity was used to assess seroconversion.The first dose of vaccine induced seroconversion in 91.7% of beneficiaries. Nearly one-third (30.2%) of them had high antibody titers, and it showed a significant association with female gender (9.6 ± 5.5 vs. 7.6 ± 5.6) and younger age (P = 0.008). In addition, those with previous COVID infection showed a more robust immune response when compared to others (P = 0.001).Seroconversion rate of more than 90% offers a promising hope toward successful pandemic control. In the current scenario, the inability to attain the targeted coverage due to an upsurge in vaccine hesitancy, compounded with only lower proportion of seroconversion in elderly, faster rollout of the vaccines without any age limit, will help achieve the herd threshold more rapidly." @default.
- W4285260149 created "2022-07-14" @default.
- W4285260149 creator A5004589347 @default.
- W4285260149 creator A5010551853 @default.
- W4285260149 creator A5051798670 @default.
- W4285260149 creator A5056746821 @default.
- W4285260149 creator A5057058196 @default.
- W4285260149 creator A5060199964 @default.
- W4285260149 creator A5085573933 @default.
- W4285260149 date "2022-01-01" @default.
- W4285260149 modified "2023-09-25" @default.
- W4285260149 title "COVID-19 vaccines portray the bright side of human creativity, but it means nothing until they prove their worth: A Study on Seroconversion after the first Dose of Covishield vaccine in central Kerala" @default.
- W4285260149 cites W2151165850 @default.
- W4285260149 cites W2469183780 @default.
- W4285260149 cites W2736112898 @default.
- W4285260149 cites W2791508868 @default.
- W4285260149 cites W3021544284 @default.
- W4285260149 cites W3021816206 @default.
- W4285260149 cites W3027204812 @default.
- W4285260149 cites W3083750089 @default.
- W4285260149 cites W3097453900 @default.
- W4285260149 cites W3111590711 @default.
- W4285260149 cites W3119364446 @default.
- W4285260149 cites W3138958270 @default.
- W4285260149 cites W4292646794 @default.
- W4285260149 doi "https://doi.org/10.4103/ijcm.ijcm_671_21" @default.
- W4285260149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36034264" @default.
- W4285260149 hasPublicationYear "2022" @default.
- W4285260149 type Work @default.
- W4285260149 citedByCount "0" @default.
- W4285260149 crossrefType "journal-article" @default.
- W4285260149 hasAuthorship W4285260149A5004589347 @default.
- W4285260149 hasAuthorship W4285260149A5010551853 @default.
- W4285260149 hasAuthorship W4285260149A5051798670 @default.
- W4285260149 hasAuthorship W4285260149A5056746821 @default.
- W4285260149 hasAuthorship W4285260149A5057058196 @default.
- W4285260149 hasAuthorship W4285260149A5060199964 @default.
- W4285260149 hasAuthorship W4285260149A5085573933 @default.
- W4285260149 hasBestOaLocation W42852601491 @default.
- W4285260149 hasConcept C106192422 @default.
- W4285260149 hasConcept C126322002 @default.
- W4285260149 hasConcept C159047783 @default.
- W4285260149 hasConcept C159654299 @default.
- W4285260149 hasConcept C203014093 @default.
- W4285260149 hasConcept C22070199 @default.
- W4285260149 hasConcept C2777451964 @default.
- W4285260149 hasConcept C2779134260 @default.
- W4285260149 hasConcept C3008058167 @default.
- W4285260149 hasConcept C524204448 @default.
- W4285260149 hasConcept C71924100 @default.
- W4285260149 hasConcept C89623803 @default.
- W4285260149 hasConceptScore W4285260149C106192422 @default.
- W4285260149 hasConceptScore W4285260149C126322002 @default.
- W4285260149 hasConceptScore W4285260149C159047783 @default.
- W4285260149 hasConceptScore W4285260149C159654299 @default.
- W4285260149 hasConceptScore W4285260149C203014093 @default.
- W4285260149 hasConceptScore W4285260149C22070199 @default.
- W4285260149 hasConceptScore W4285260149C2777451964 @default.
- W4285260149 hasConceptScore W4285260149C2779134260 @default.
- W4285260149 hasConceptScore W4285260149C3008058167 @default.
- W4285260149 hasConceptScore W4285260149C524204448 @default.
- W4285260149 hasConceptScore W4285260149C71924100 @default.
- W4285260149 hasConceptScore W4285260149C89623803 @default.
- W4285260149 hasIssue "2" @default.
- W4285260149 hasLocation W42852601491 @default.
- W4285260149 hasLocation W42852601492 @default.
- W4285260149 hasLocation W42852601493 @default.
- W4285260149 hasOpenAccess W4285260149 @default.
- W4285260149 hasPrimaryLocation W42852601491 @default.
- W4285260149 hasRelatedWork W2005425589 @default.
- W4285260149 hasRelatedWork W2072892746 @default.
- W4285260149 hasRelatedWork W2082037542 @default.
- W4285260149 hasRelatedWork W2126782227 @default.
- W4285260149 hasRelatedWork W2127387725 @default.
- W4285260149 hasRelatedWork W2804461521 @default.
- W4285260149 hasRelatedWork W4210792408 @default.
- W4285260149 hasRelatedWork W4381942459 @default.
- W4285260149 hasRelatedWork W2183587730 @default.
- W4285260149 hasRelatedWork W2203580449 @default.
- W4285260149 hasVolume "47" @default.
- W4285260149 isParatext "false" @default.
- W4285260149 isRetracted "false" @default.
- W4285260149 workType "article" @default.